ArticleUpdates in surgery2026
Heterogeneity in the management of patients with locally advanced pancreatic cancer: current surgeons' perspective and lessons for the future.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of patients with locally advanced pancreatic cancer (LAPC) in the era of promising neoadjuvant treatments and “conversion” surgery remains challenging. This survey sought to register the current practices and perspectives of recognized pancreatic surgeons and provide valuable insights for future research. An online survey consisting of 18 questions on real-life challenging clinical situations was conducted using Google Forms. Participants were asked about their approach in the management of a 60-year-old patient with LAPC after 8 weeks of neoadjuvant chemotherapy in different settings of response to the neoadjuvant treatments and of intraoperative findings. Seventy-three respondents from 19 different countries completed the survey. 74% (54/73) of the respondents declared working at centers performing more than 50 pancreatic resections per year. Overall, the answers among participants were very heterogeneous. There was no consensus regarding the optimal duration of neoadjuvant chemotherapy, nor on the appropriate timing and indications for regimen modification. Similarly, the criteria for surgical exploration, the intraoperative strategies in case of venous or arterial involvement, and the role of perivascular frozen-section analysis in guiding intraoperative decisions remained debated among the participating surgeons. Here, the lack of knowledge in the current literature on these issues and the subsequent reliance on individual expertise may account for this heterogeneity. Further research efforts are required to address existing knowledge gaps and to advance and standardize the management of patients with LAPC.
Indexed as
Identifiers
42053953What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.